Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00364780 · ClinicalTrials.gov registry record · Phase 2
Study of XL647 in Subjects With Non-Small-Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Kadmon Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 7
- Study locations
NCT00364780: Completed Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Kadmon Corporation.
NCT00364780 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by Kadmon Corporation. The registered enrollment target is 55 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (92% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00364780, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by Kadmon Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this phase II study is to determine the safety, tolerability, and activity of XL647 in previously untreated subjects with non-small cell lung cancer (NSCLC). XL647 is a small molecule that potently inhibits multiple receptor kinases, including EGFR, VEGFR2 (KDR), ErbB2, and EphB4. Sensitivity to EGFR inhibitors has been linked to specific EGFR mutations and associated with certain clinical characteristics in patients with NSCLC (eg, female, minimal and remote smoking history, and adenocarcinoma histology).
Conditions Studied
Interventions
- DRUG XL647
Study Locations (7)
Illinois
- University of Chicago - Chicago
- Carle Cancer Center - Urbana
Florida
- Hematology Oncology Associates of the Treasure Coast - Port Saint Lucie
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Wayne University, Wertz Clinical Cancer Center, Karmanos Center - Detroit
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Case Western Reserve University, University Hospitals of Cleveland - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2006-07 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
What the finished NCT00364780 record still lists
NCT00364780 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which XL647 is the first listed.
NCT00364780 lists 7 locations in 6 states (Illinois, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00364780 about?
NCT00364780 is a clinical study titled "Study of XL647 in Subjects With Non-Small-Cell Lung Cancer". The purpose of this phase II study is to determine the safety, tolerability, and activity of XL647 in previously untreated subjects with non-small cell lung cancer (NSCLC). XL647 is a small molecule that potently inhibits multiple receptor kinases, including EGFR, VEGFR2 (KDR), ErbB2, and EphB4. Sen...
What is the current status of trial NCT00364780?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2006-07. Estimated completion is 2010-08.
What conditions does trial NCT00364780 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT00364780?
The interventions under investigation include: XL647 (DRUG).
Who is sponsoring clinical trial NCT00364780?
This trial is sponsored by Kadmon Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00364780 being conducted?
This trial has 7 study locations across Florida, Illinois, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00364780's enrollment target sits among peer trials
55 326th of 454 higher than 129 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia